Evidence map›Paper›PMID 36944946›Full record

ReviewJournal of nanobiotechnology2023

Active targeting schemes for nano-drug delivery systems in osteosarcoma therapeutics.

Pengzhi Shi, Zhangrong Cheng, Kangcheng Zhao, Yuhang Chen, Anran Zhang, Weikang Gan, Yukun Zhang

Open access · goldFull text readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of nanobiotechnology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
66citing papers in PubMed, 1 pooled it
17.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

66 citing papers in PubMed, 1 synthesis or guideline pooled it, 172 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Anticancer Activity of Green Synthesized ZnO Nanoparticles fromNanomaterials (Basel, Switzerland) · 2026
    Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Hierarchical Targeting of TREM2Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Musculoskeletal disorders: does cuproptosis hold the key?Frontiers in cell and developmental biology · 2026
    Review
  17. Review
  18. Review
  19. Review
  20. Review

6 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Pengzhi Shi *Department of Orthopedics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Zhangrong Cheng *Department of Orthopedics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Kangcheng Zhao *Department of Orthopedics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Yuhang ChenDepartment of Orthopedics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Anran ZhangDepartment of Orthopedics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Weikang GanDepartment of Orthopedics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Yukun ZhangDepartment of Orthopedics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China. zhangyukuncom@126.com.
Union Hospital · CNHuazhong University of Science and Technology · CN

Funding

National Natural Science Foundation of China 81974348
6 · The paper itself

Abstract

Osteosarcoma, the most common malignant tumor of the bone, seriously influences people's lives and increases their economic burden. Conventional chemotherapy drugs achieve limited therapeutic effects owing to poor targeting and severe systemic toxicity. Nanocarrier-based drug delivery systems can significantly enhance the utilization efficiency of chemotherapeutic drugs through targeting ligand modifications and reduce the occurrence of systemic adverse effects. A variety of ligand-modified nano-drug delivery systems have been developed for different targeting schemes. Here we review the biological characteristics and the main challenges of current drug therapy of OS, and further elaborate on different targeting schemes and ligand selection for nano-drug delivery systems of osteosarcoma, which may provide new horizons for the development of advanced targeted drug delivery systems in the future.

Indexed as

Antineoplastic AgentsBone NeoplasmsNanoparticlesOsteosarcomaDrug CarriersHumansLigandsNanoparticle Drug Delivery SystemAntineoplastic AgentsDrug CarriersLigandsNanoparticle Drug Delivery SystemActive targetingNano-drug delivery systemOsteosarcomaPassive targetingTargeting ligand

Identifiers

PMID36944946
PMCPMC10031984
OpenAlexW4328050642

What Socratic holds

Textfull text, public
LicenceCC BY
measurements read44
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.